Is PET/CT essential in the diagnosis and follow-up of temporal arteritis?

Samson, 2017, Recent advances in our understanding of giant cell arteritis pathogenesis, Autoimmun Rev, 16, 833, 10.1016/j.autrev.2017.05.014 Regent, 2017, Molecular analysis of vascular smooth muscle cells from patients with giant cell arteritis: targeting endothelin-1 receptor to control proliferation, Autoimmun Rev, 16, 398, 10.1016/j.autrev.2017.02.006 Legendre, 2017, Anti-endothelial cell antibodies in vasculitis: a systematic review, Autoimmun Rev, 16, 146, 10.1016/j.autrev.2016.12.012 Misra, 2017, A scoping review of the use of non-biologic disease modifying anti-rheumatic drugs in the management of large vessel vasculitis, Autoimmun Rev, 16, 179, 10.1016/j.autrev.2016.12.009 Ferfar, 2016, Biotherapies in large vessel vasculitis, Autoimmun Rev, 15, 544, 10.1016/j.autrev.2016.02.012 Espitia, 2016, Comparison of idiopathic (isolated) aortitis and giant cell arteritis-related aortitis. A French retrospective multicenter study of 117 patients, Autoimmun Rev, 15, 571, 10.1016/j.autrev.2016.02.016 Berti, 2015, Giant cell arteritis restricted to the limb arteries: an overlooked clinical entity, Autoimmun Rev, 14, 352, 10.1016/j.autrev.2014.12.005 Muratore, 2016, Imaging of vasculitis: state of the art, Best Pract Res Clin Rheumatol, 30, 688, 10.1016/j.berh.2016.09.010 Salvarani, 2008, Polymyalgia rheumatica and giant-cell arteritis, Lancet, 372, 234, 10.1016/S0140-6736(08)61077-6 Gonzalez-Gay, 2004, Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain: a population-based study, Medicine (Baltimore), 83, 335, 10.1097/01.md.0000145366.40805.f8 Nuenninghoff, 2003, Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50years, Arthritis Rheum, 48, 3522, 10.1002/art.11353 García-Martínez, 2008, Development of aortic aneurysm/dilatation during the follow-up of patients with giant cell arteritis: a cross-sectional screening of fifty-four prospectively followed patients, Arthritis Rheum, 59, 422, 10.1002/art.23315 Soriano, 2017, Visual loss and other cranial ischaemic complications in giant cell arteritis, Nat Rev Rheumatol, 13, 476, 10.1038/nrrheum.2017.98 Brack, 1999, Disease pattern in cranial and large-vessel giant cell arteritis, Arthritis Rheum, 42, 311, 10.1002/1529-0131(199902)42:2<311::AID-ANR14>3.0.CO;2-F Muratore, 2015, Large-vessel giant cell arteritis: a cohort study, Rheumatology (Oxford), 54, 463, 10.1093/rheumatology/keu329 Schmidt, 2008, Ultrasound of proximal upper extremity arteries to increase the diagnostic yield in large-vessel giant cell arteritis, Rheumatology (Oxford), 47, 96, 10.1093/rheumatology/kem322 Czihal, 2012, Sonographic and clinical pattern of extracranial and cranial giant cell arteritis, Scand J Rheumatol, 41, 231, 10.3109/03009742.2011.641581 Ghinoi, 2012, Large-vessel involvement in recent-onset giant cell arteritis: a case–control colour-Doppler sonography study, Rheumatology (Oxford), 51, 730, 10.1093/rheumatology/ker329 Agard, 2008, Aortic involvement in recent-onset giant cell (temporal) arteritis: a case-control prospective study using helical aortic computed tomodensitometric scan, Arthritis Rheum, 59, 670, 10.1002/art.23577 Prieto-González, 2012, Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography, Ann Rheum Dis, 71, 1170, 10.1136/annrheumdis-2011-200865 Blockmans, 2006, Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients, Arthritis Rheum, 55, 131, 10.1002/art.21699 Muratore, 2016, Histopathologic findings of patients with biopsy-negative giant cell arteritis compared to those without arteritis: a population-based study, Arthritis Care Res (Hoboken), 68, 865, 10.1002/acr.22736 Hunder, 1990, The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis, Arthritis Rheum, 33, 1122, 10.1002/art.1780330810 Calamia, 1981, Giant cell arteritis (temporal arteritis) presenting as fever of undetermined origin, Arthritis Rheum, 24, 1414, 10.1002/art.1780241113 Meller, 2003, Early diagnosis and follow-up of aortitis with [(18)F]FDG PET and MRI, Eur J Nucl Med Mol Imaging, 30, 730, 10.1007/s00259-003-1144-y Fuchs, 2012, The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis, Eur J Nucl Med Mol Imaging, 39, 344, 10.1007/s00259-011-1967-x Pipitone, 2008, Role of imaging studies in the diagnosis and follow-up of large-vessel vasculitis: an update, Rheumatology (Oxford), 47, 403, 10.1093/rheumatology/kem379 Besson, 2011, Diagnostic performance of 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a systematic review and meta-analysis, Eur J Nucl Med Mol Imaging, 38, 764 Stellingwerff, 2015, Different scoring methods of FDG PET/CT in giant cell arteritis: need for standardization, Medicine (Baltimore), 94, 10.1097/MD.0000000000001542 Sondag, 2016, Utility of 18F-fluoro-dexoxyglucose positron emission tomography for the diagnosis of polymyalgia rheumatica: a controlled study, Rheumatology (Oxford), 55, 1452, 10.1093/rheumatology/kew202 Yamashita, 2012, Whole-body fluorodeoxyglucose positron emission tomography/computed tomography in patients with active polymyalgia rheumatica: evidence for distinctive bursitis and large-vessel vasculitis, Mod Rheumatol, 22, 705, 10.3109/s10165-011-0581-x Blockmans, 2008, Relationship between fluorodeoxyglucose uptake in the large vessels and late aortic diameter in giant cell arteritis, Rheumatology (Oxford), 47, 1179, 10.1093/rheumatology/ken119 de Boysson, 2016, 18F-fluorodeoxyglucose positron emission tomography and the risk of subsequent aortic complications in giant-cell arteritis: a multicenter cohort of 130 patients, Medicine (Baltimore), 95, 10.1097/MD.0000000000003851 Blockmans, 1999, New arguments for a vasculitic nature of polymyalgia rheumatica using positron emission tomography, Rheumatology, 38, 444, 10.1093/rheumatology/38.5.444 Blockmans, 2000, Positron emission tomography in giant cell arteritis and polymyalgia rheumatica: evidence for inflammation of the aortic arch, Am J Med, 108, 246, 10.1016/S0002-9343(99)00424-6 Blockmans, 2007, Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients, Rheumatology, 46, 672, 10.1093/rheumatology/kel376 Planté-Bordeneuve T, Henckaerts L, Lerut E, Verbeke E, Blockmans D. Not every case of temporal arteritis is giant cell arteritis. Microscopic polyangiitis involving the temporal artery - a case report and review of the literature. J Clin Rheum, [in press]. Stone, 2017, Tocilizumab for sustained glucocorticoid-free remission in giant cell arteritis, New Engl J Med, 377, 317, 10.1056/NEJMoa1613849 Blockmans, 2003, The use of (18F) fluoro-deoxyglucose positron emission tomography in the assessment of large vessel vasculitis, Clin Exp Rheumatol, 21, S15 Brodmann, 2004, The role of 2-18-F-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of giant cell arteritis of the temporal arteries, Rheumatology, 43, 241, 10.1093/rheumatology/keh025